Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGON NYSE:DNA NASDAQ:IBRX NASDAQ:NMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$64.25$67.23$23.65▼$75.50$5.67B0.41849,252 shs652,815 shsDNAGinkgo Bioworks$8.42+0.1%$7.51$5.37▼$17.58$549.80M1.771.30 million shs874,205 shsIBRXImmunityBio$7.22$7.75$1.95▼$12.43$7.56B0.0213.58 million shs17.87 million shsNMRANeumora Therapeutics$1.85$2.20$0.66▼$3.65$342.77M3.021.46 million shs1.36 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology0.00%-4.00%-6.45%+10.19%+152.56%DNAGinkgo Bioworks0.00%+9.38%+7.02%-5.17%+20.41%IBRXImmunityBio0.00%-9.41%-2.96%-26.55%+185.38%NMRANeumora Therapeutics0.00%+0.54%-17.78%-46.38%+172.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$64.25$67.23$23.65▼$75.50$5.67B0.41849,252 shs652,815 shsDNAGinkgo Bioworks$8.42+0.1%$7.51$5.37▼$17.58$549.80M1.771.30 million shs874,205 shsIBRXImmunityBio$7.22$7.75$1.95▼$12.43$7.56B0.0213.58 million shs17.87 million shsNMRANeumora Therapeutics$1.85$2.20$0.66▼$3.65$342.77M3.021.46 million shs1.36 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology0.00%-4.00%-6.45%+10.19%+152.56%DNAGinkgo Bioworks0.00%+9.38%+7.02%-5.17%+20.41%IBRXImmunityBio0.00%-9.41%-2.96%-26.55%+185.38%NMRANeumora Therapeutics0.00%+0.54%-17.78%-46.38%+172.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGONCG Oncology 2.71Moderate Buy$81.7327.20% UpsideDNAGinkgo Bioworks 1.67Reduce$8.500.99% UpsideIBRXImmunityBio 2.71Moderate Buy$14.2096.68% UpsideNMRANeumora Therapeutics 2.56Moderate Buy$7.67314.41% UpsideCurrent Analyst Ratings BreakdownLatest CGON, NMRA, DNA, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/20/2026IBRXImmunityBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/19/2026CGONCG Oncology Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform5/18/2026CGONCG Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.005/14/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$77.00 ➝ $82.005/11/2026CGONCG Oncology JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$91.00 ➝ $96.005/11/2026CGONCG Oncology Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$79.00 ➝ $81.005/11/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.00 ➝ $77.005/11/2026CGONCG Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$77.00 ➝ $80.005/8/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$12.005/5/2026IBRXImmunityBio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGONCG Oncology$4.04M1,402.69N/AN/A$12.38 per share5.19DNAGinkgo Bioworks$170.15M3.23N/AN/A$6.78 per share1.24IBRXImmunityBio$113.29M66.75N/AN/A($0.83) per share-8.70NMRANeumora TherapeuticsN/AN/AN/AN/A$0.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGONCG Oncology-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%8/7/2026 (Estimated)DNAGinkgo Bioworks-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)IBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)NMRANeumora Therapeutics-$236.93M-$1.33N/AN/AN/AN/A-181.70%-119.15%8/5/2026 (Estimated)Latest CGON, NMRA, DNA, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026CGONCG Oncology-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026NMRANeumora Therapeutics-$0.32-$0.30+$0.02-$0.30N/AN/A3/30/2026Q4 2025NMRANeumora Therapeutics-$0.34-$0.35-$0.01-$0.35N/AN/A2/27/2026Q4 2025CGONCG Oncology-$0.61-$0.51+$0.10-$0.51N/A$2.32 million2/26/2026Q4 2025DNAGinkgo Bioworks-$1.80-$1.42+$0.38-$1.42$37.57 million$33.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGONCG OncologyN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGONCG OncologyN/A31.3031.25DNAGinkgo BioworksN/A5.155.15IBRXImmunityBioN/A6.676.66NMRANeumora Therapeutics0.755.095.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGONCG Oncology26.56%DNAGinkgo Bioworks78.63%IBRXImmunityBio8.58%NMRANeumora Therapeutics47.65%Insider OwnershipCompanyInsider OwnershipCGONCG Oncology4.80%DNAGinkgo Bioworks12.69%IBRXImmunityBio69.48%NMRANeumora Therapeutics26.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGONCG Oncology6188.20 million83.97 millionOptionableDNAGinkgo Bioworks64065.32 million57.03 millionOptionableIBRXImmunityBio5901.05 billion319.65 millionOptionableNMRANeumora Therapeutics108185.28 million135.37 millionOptionableCGON, NMRA, DNA, and IBRX HeadlinesRecent News About These CompaniesNeumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor CatalystMay 22 at 12:50 PM | tipranks.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 17, 2026 | americanbankingnews.comNeumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare ConferenceMay 12, 2026 | globenewswire.comNeumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 7, 2026 | globenewswire.comNeumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comNeumora Therapeutics, Inc. (NMRA) Gets a Buy from GuggenheimApril 25, 2026 | theglobeandmail.comNeumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy RatingApril 14, 2026 | tipranks.comNeumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to ExplodeApril 12, 2026 | insidermonkey.comNeumora Therapeutics (NMRA) price target increased by 19.25% to 9.33April 10, 2026 | msn.comNeumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comNMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law FirmApril 1, 2026 | globenewswire.comNeumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call SummaryApril 1, 2026 | finance.yahoo.comNeumora Therapeutics Maps High-Stakes Catalyst Road AheadMarch 31, 2026 | tipranks.comNeumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital AccessMarch 31, 2026 | tipranks.comNeumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ...March 30, 2026 | finance.yahoo.comNeumora Therapeutics: Charting a Course for Breakthroughs in Brain DiseasesMarch 30, 2026 | news.themarketisopen.comNNeumora tops Q4 earnings forecasts as pipeline advances, shares slipMarch 30, 2026 | msn.comNeumora Therapeutics: Downgrading After Navacaprant Development SetbackMarch 30, 2026 | seekingalpha.comNeumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comNeumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comNeumora Therapeutics (NMRA) price target decreased by 16.15% to 7.82March 28, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGON, NMRA, DNA, and IBRX Company DescriptionsCG Oncology NASDAQ:CGON$64.25 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$64.25 0.00 (0.00%) As of 05/22/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Ginkgo Bioworks NYSE:DNA$8.42 +0.01 (+0.08%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$8.65 +0.24 (+2.82%) As of 05/22/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.ImmunityBio NASDAQ:IBRX$7.22 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.22 0.00 (-0.07%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Neumora Therapeutics NASDAQ:NMRA$1.85 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.90 +0.05 (+2.97%) As of 05/22/2026 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
